translation agency

Health-E
Antibodies offer AIDS vaccine clue

<p>Anso Thom</p>


October 22, 2012

A response to the HI-Virus in two HIV positive women, which enabled them to make potent antibodies that would kill most of the HIV types from around the world, has provided South African reseachers with potential clues for the development of an AIDS vaccine.

The study published on Sunday in the journal, Nature Medicine, describes how a unique change in the outer covering of the virus found in two HIV infected South African women enabled them to make potent antibodies which are able to kill up to 88% of HIV types from around the world. The discovery, described as “groundbreaking” provides an important new approach that could be useful in making an AIDS vaccine, according to the researchers.

For the last five years, the Centre for the AIDS Programme of Research in SA (CAPRISA) consortium, involving scientists from the National Institute for Communicable Diseases (NICD) in Johannesburg, the University of KwaZulu-Natal, University of Cape Town and University of the Witwatersrand, has been studying how certain HIV-infected people develop very powerful antibody responses.

These antibodies are referred to as broadly “neutralising antibodies” because they kill a wide range of HIV types from different parts of the world.

The CAPRISA team initially discovered that two KwaZulu-Natal women, one of whom participated in the CAPRISA 004 tenofovir gel study, could make these rare antibodies.

Through long-term follow-up laboratory studies on these two women, the team led by NICD-based scientists discovered that a sugar (known as a glycan) on the surface protein coat of the virus at a specific position (referred to as position 332) forms a site of vulnerability in the virus and enables the body to mount a broadly neutralising antibody response.

NICD lead scientist Dr Penny Moore said: “Understanding this elaborate game of cat and mouse between HIV and the immune response of the infected person has provided valuable insights into how broadly neutralising antibodies arise”.

Professor Lynn Morris, Head of AIDS Research at the NICD explained, “We were surprised to find that the virus that caused infection in many cases did not have this antibody target on its outer covering. But over time, the virus was pressured by body?s immune reaction to cover itself with the sugar that formed a point of vulnerability, and so allowed the development of antibodies that hit that weak spot”.

CAPRISA Director Professor Salim Abdool Karim explained that broadly neutralising antibodies are considered to be the key to making an AIDS vaccine.

While their existence has been known for a while, highly potent forms of broadly neutralising antibodies against HIV were only identified about 3 years ago.

Until now, it was not known how the human body is able to make these antibodies.

This study has discovered one mechanism by which these antibodies may be made.

To make this discovery, the research team studied the target of some of these antibodies, a sugar that coats the surface protein of HIV, forming a site of vulnerability.

By tracing back the evolution of the virus that elicited these antibodies, the team showed that this particular weak point was absent from the virus that first infected these women.

However, under constant pressure from other less powerful antibodies that develop in all infected people, their HIV was forced to expose this vulnerability over time. This allowed the broadly neutralising antibodies to develop. Analysis of a large number of other viruses from throughout the world, performed in collaboration with scientists from the University of North Carolina and Harvard University, suggest that the vulnerability at position 332 may be present at the time of infection in about two thirds of subtype C viruses (the subtype most common in Africa).

Hence, if a vaccine is developed to target this glycan only, it may not be able to uniformly neutralise all subtype C viruses; as a result AIDS vaccines may need to attack multiple targets on the virus.

This research was funded by the South African government's Department of Science and Technology, the US National Institutes for Health and the Bill & Melinda Gates.

 



www.aegis.org